Semaglutide is contraindicated in patients with a personal or family history of certain types of thyroid cancer, specifically thyroid C-cell tumors such as medullary thyroid carcinoma (MTC), or in patients with multiple endocrine neoplasia syndrome type 2 (MEN 2)
Overall, proper oral administration may support systemic and gut-specific repair effectively, while localized injections or intravenous therapy is more suitable for targeted musculoskeletal issues
Standard FDA-approved escalation The protocol moves in 2.5 mg increments, each held for at least four weeks: Weeks 1 to 4: 2.5 mg once weekly (initiation dose, not therapeutic) Weeks 5 to 8: 5 mg once weekly (first therapeutic dose) Weeks 9 to 12: 7.5 mg once weekly Weeks 13 to 16: 10 mg once weekly Weeks 17 to 20: 12.5 mg once weekly Week 21 onward: 15 mg once weekly (maximum dose) Not everyone reaches 15 mg
Comparing Standard Doses vs
Research Pentadecapeptide BPC 157 Enhances the Growth Hormone Receptor Expression in Tendon Fibroblasts Chang CH, Tsai WC, Hsu YH, Pang JH